Shots:
- The EC has approved Zepzelca (Lurbinectedin) + Tecentriq (Atezolizumab) as a 1L therapy for adults with ES-SCLC whose disease remains stable after initial treatment with Tecentriq, carboplatin, & etoposide
- Approval was based on P-III (IMforte) trial results, showing Zepzelca + Tecentriq reduced the risk of progression or death by 46% & death risk by 27% vs Tecentriq alone. Trial showed mOS of 13.2 vs 10.6mos. & mPFS of 5.4 vs 2.1 mos. for Zepzelca + Tecentriq vs Tecentriq alone, following four induction therapy cycles from randomization; data were presented at ASCO’25 & published in The Lancet
- Immedica holds Zepzelca distribution rights through its strategic partnership with PharmaMar across the Nordics, UK & Ireland, Central and Eastern Europe, the Middle East, and North Africa
Ref: Immedica | Image: Immedica | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
